Publication:
Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy

dc.contributor.coauthorArf, Serra
dc.contributor.coauthorSayman Muslubaş, Işıl
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAkbay, Aylin Koç
dc.contributor.kuauthorMandel, Nil Molinas
dc.contributor.kuauthorÖnal, Sumru
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.kuauthorUludağ, Günay
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:43:00Z
dc.date.issued2016
dc.description.abstractPurpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and negative work-up for cancer was diagnosed with npAIR. Visual acuity and ancillary tests were normal except abnormal ERG in both eyes. The patient was given one course of rituximab 375 mg/m2/week for 4 weeks and cyclophosphamide 1 gr/m2/month for 6 months. A second course of rituximab was necessary as autoantibody titers showed no change and as new antibodies were noted after treatment with rituximab and cyclophosphamide. Electroretinography was repeated after the first course of rituximab, after cyclophosphamide, and the second course of rituximab therapy. Conclusions and Importance: Rituximab therapy led to marked improvement in full-field ERG readings and regression of symptoms was reported by the patient after rituximab infusions. The effect of rituximab in npAIR was objectively demonstrated with ERG.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume2
dc.identifier.doi10.1016/j.ajoc.2016.03.007
dc.identifier.issn2451-9936
dc.identifier.scopus2-s2.0-85009070276
dc.identifier.urihttps://doi.org/10.1016/j.ajoc.2016.03.007
dc.identifier.urihttps://hdl.handle.net/20.500.14288/13419
dc.keywordsAutoimmune retinopathy
dc.keywordsElectrophysiology
dc.keywordsElectroretinography
dc.keywordsNeoplastic
dc.keywordsNonparaneoplastic
dc.keywordsRituximab
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofAmerican Journal of Ophthalmology Case Reports
dc.subjectOphthalmology
dc.titleElectroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorUludağ, Günay
local.contributor.kuauthorÖnal, Sumru
local.contributor.kuauthorSelçukbiricik, Fatih
local.contributor.kuauthorAkbay, Aylin Koç
local.contributor.kuauthorMandel, Nil Molinas
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files